This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

RBL001/RBL002

BioNTech AG

Drug Names(s): IVAC Vaccine

Description: BioNTech is developing RNA-based cancer vaccines targeted against mutations identified through full sequencing of individual tumors. The program identifies mutations through full-genome sequencing, and designed mRNA analogs designed to express protein with that particular mutation which may then stimulate an immune response.

This record for RBL001/RBL002 follows RNAs targeted two melanoma mutations. We will edit this record as more details become released.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug